LncRNA PANDAR 作为中国癌症的预后标志物。

LncRNA PANDAR as a prognostic marker in Chinese cancer.

机构信息

Department of neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan province, People's Republic of China.

Department of thoracic surgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan province, People's Republic of China.

出版信息

Clin Chim Acta. 2017 Dec;475:172-177. doi: 10.1016/j.cca.2017.10.020. Epub 2017 Oct 21.

DOI:10.1016/j.cca.2017.10.020

PMID:29066211

Abstract

BACKGROUND

LncRNA promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) is reportedly dysregulated in various cancers. We performed this meta-analysis to clarify the efficacy of PANDAR as a prognostic marker in malignant tumors.

METHODS

The PubMed, Medline, OVID, Cochrane Library, and Web of Science databases were searched from inception to July 3, 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between PANDAR expression and overall survival (OS). Odds ratios (ORs) were calculated to assess the association between PANDAR expression and pathological parameters.

RESULTS

Eight original studies covering 1,132 cancer patients were included. The pooled HR suggested that high PANDAR expression correlated with poor OS (pooled HR=1.60, 95% CI: 1.09-2.33) in cancer patients. PANDAR expression was also related to lymph node metastasis (OR=3.26, 95% CI: 2.09-5.09), advanced tumor stage (OR=3.60, 95% CI: 2.39-5.44) and histological grade (OR=2.75, 95% CI: 1.73-4.38). Begg's funnel plot showed no evidence of obvious asymmetry for overall survival and lymph node metastasis.

CONCLUSIONS

Thus high PANDAR expression appears predictive of poor OS, lymph node metastasis, advanced tumor stage and histological grade in multiple cancers. This suggests PANDAR expression could serve as a biomarker of poor prognosis in Chinese cancer patients.

摘要

背景

据报道，CDKN1A 反义 DNA 损伤激活 RNA（PANDAR）的 lncRNA 启动子在各种癌症中失调。我们进行了这项荟萃分析，以阐明 PANDAR 作为恶性肿瘤预后标志物的功效。

方法

从建库到 2017 年 7 月 3 日，我们在 PubMed、Medline、OVID、Cochrane 图书馆和 Web of Science 数据库中进行了搜索。计算风险比（HRs）和 95%置信区间（CIs）以探讨 PANDAR 表达与总生存（OS）之间的关系。计算比值比（ORs）以评估 PANDAR 表达与病理参数之间的关联。

结果

纳入了 8 项原始研究，共涵盖 1132 名癌症患者。汇总的 HR 表明，癌症患者中 PANDAR 高表达与 OS 不良相关（汇总 HR=1.60，95%CI：1.09-2.33）。PANDAR 表达还与淋巴结转移（OR=3.26，95%CI：2.09-5.09）、晚期肿瘤分期（OR=3.60，95%CI：2.39-5.44）和组织学分级（OR=2.75，95%CI：1.73-4.38）相关。Begg 漏斗图显示总体生存和淋巴结转移无明显不对称证据。